Two cases of severe childhood-onset psoriasis successfully treated with risankizumab in patients with Down syndrome and morbid obesity
Saved in:
| Main Authors: | Yoshiaki Hara, Tomomitsu Miyagaki, Tatsuro Okano, Takafumi Kadono, Hidenori Watabe |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Journal of Cutaneous Immunology and Allergy |
| Subjects: | |
| Online Access: | https://www.frontierspartnerships.org/articles/10.3389/jcia.2025.15043/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series
by: Andrea D'Arino, et al.
Published: (2025-07-01) -
Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison
by: Leyla Baykal Selçuk, et al.
Published: (2025-04-01) -
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study
by: Luciano Ibba, et al.
Published: (2024-12-01) -
Demographics, Clinical Characteristics, and Treatment Patterns in Patients with Psoriasis: Insights from the Saudi Arabia Psoriasis Registry (PSORSA)
by: Mohammad Ibrahim Fatani, et al.
Published: (2025-05-01) -
Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification
by: Bruce Strober, et al.
Published: (2025-07-01)